DK1355940T3 - Urotensin II-agonister og -antagonister - Google Patents

Urotensin II-agonister og -antagonister

Info

Publication number
DK1355940T3
DK1355940T3 DK01987763T DK01987763T DK1355940T3 DK 1355940 T3 DK1355940 T3 DK 1355940T3 DK 01987763 T DK01987763 T DK 01987763T DK 01987763 T DK01987763 T DK 01987763T DK 1355940 T3 DK1355940 T3 DK 1355940T3
Authority
DK
Denmark
Prior art keywords
urotensin
agonists
antagonists
features
antagonist
Prior art date
Application number
DK01987763T
Other languages
English (en)
Inventor
David H Coy
Wojciech J Rossowski
John E Taylor
Original Assignee
Univ Tulane
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane, Sod Conseils Rech Applic filed Critical Univ Tulane
Application granted granted Critical
Publication of DK1355940T3 publication Critical patent/DK1355940T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK01987763T 2000-10-20 2001-10-19 Urotensin II-agonister og -antagonister DK1355940T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24189600P 2000-10-20 2000-10-20
PCT/US2001/050724 WO2002032932A2 (en) 2000-10-20 2001-10-19 Urotensin-ii agonists and antagonists

Publications (1)

Publication Number Publication Date
DK1355940T3 true DK1355940T3 (da) 2008-01-07

Family

ID=22912605

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01987763T DK1355940T3 (da) 2000-10-20 2001-10-19 Urotensin II-agonister og -antagonister

Country Status (21)

Country Link
US (2) US7241737B2 (da)
EP (1) EP1355940B1 (da)
JP (2) JP4081369B2 (da)
KR (3) KR100820896B1 (da)
AT (1) ATE374786T1 (da)
AU (2) AU2002232903B2 (da)
BR (1) BR0114737A (da)
CA (1) CA2425804A1 (da)
CZ (1) CZ299402B6 (da)
DE (1) DE60130802T2 (da)
DK (1) DK1355940T3 (da)
ES (1) ES2291372T3 (da)
HU (1) HUP0301384A3 (da)
IL (2) IL155127A0 (da)
MX (1) MXPA03003297A (da)
NO (1) NO20031699L (da)
PL (1) PL366327A1 (da)
PT (1) PT1355940E (da)
RU (1) RU2263679C2 (da)
WO (1) WO2002032932A2 (da)
ZA (1) ZA200302505B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014198A1 (en) * 2002-07-11 2005-01-20 Leong Ng Assays and kits for detecting and monitoring heart disease
US7939052B2 (en) * 2005-05-12 2011-05-10 Janssen Pharmaceutica Nv Method of measuring the biological activity of an urotensin II receptor
ES2410207T3 (es) * 2006-10-16 2013-07-01 The Salk Institute For Biological Studies Antagonistas de la somatostatina selectivos para receptor(SSTR2)
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
CA2733117C (en) * 2008-08-08 2016-03-22 Polyphor Ag Template-fixed peptidomimetics
RU2558921C1 (ru) * 2014-06-26 2015-08-10 Анатолий Петрович Бахтинов Способ прекращения течки у самок и остро проявляющейся охоты у самцов млекопитающих животных

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE90108T1 (de) * 1987-10-09 1993-06-15 Takeda Chemical Industries Ltd Vasokonstriktor-peptid.
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US20020107187A1 (en) * 1996-05-22 2002-08-08 Kingston David J. Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
US6262229B1 (en) * 1996-12-04 2001-07-17 Biomeasure Incorporated Somatostatin antagonists
US6159700A (en) * 1997-01-27 2000-12-12 Smithkline Beecham Corporation Method of finding agonist and antagonist to human and rat GPR14
FR2786489B1 (fr) * 1998-11-26 2002-12-27 Inst Nat Sante Rech Med Urotensines ii de mammiferes et leurs appications
JP2003527341A (ja) * 1999-11-29 2003-09-16 スミスクライン・ビーチャム・コーポレイション ウロテンシン−ii類似体
DK1372688T3 (da) * 2001-03-08 2008-08-25 Univ Tulane Somatostatin-antagonister
CN1541102A (zh) * 2001-04-09 2004-10-27 生长激素抑制素激动剂

Also Published As

Publication number Publication date
EP1355940B1 (en) 2007-10-03
MXPA03003297A (es) 2004-05-04
HUP0301384A3 (en) 2010-04-28
JP2005500244A (ja) 2005-01-06
CZ2003900A3 (cs) 2003-12-17
NO20031699L (no) 2003-06-18
ATE374786T1 (de) 2007-10-15
PL366327A1 (en) 2005-01-24
JP4081369B2 (ja) 2008-04-23
RU2263679C2 (ru) 2005-11-10
KR100707408B1 (ko) 2007-04-13
US20070287665A1 (en) 2007-12-13
ZA200302505B (en) 2005-05-30
US20050075480A1 (en) 2005-04-07
AU3290302A (en) 2002-04-29
EP1355940A2 (en) 2003-10-29
DE60130802D1 (de) 2007-11-15
NO20031699D0 (no) 2003-04-11
CA2425804A1 (en) 2002-04-25
WO2002032932A2 (en) 2002-04-25
KR20060090843A (ko) 2006-08-16
WO2002032932A3 (en) 2003-09-04
KR20060090768A (ko) 2006-08-16
HUP0301384A2 (en) 2007-11-28
IL184121A0 (en) 2007-10-31
AU2002232903B2 (en) 2005-06-30
BR0114737A (pt) 2005-06-07
KR100820896B1 (ko) 2008-04-11
PT1355940E (pt) 2007-11-08
DE60130802T2 (de) 2008-07-03
JP2006342170A (ja) 2006-12-21
KR20030081316A (ko) 2003-10-17
CZ299402B6 (cs) 2008-07-16
US7241737B2 (en) 2007-07-10
HK1059938A1 (en) 2004-07-23
ES2291372T3 (es) 2008-03-01
IL155127A0 (en) 2003-10-31
KR100795427B1 (ko) 2008-01-17

Similar Documents

Publication Publication Date Title
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
EP1017713A4 (en) CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS
ATE286897T1 (de) Morpholinderivate als antagonisten an orexinrezeptoren
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
EA200200208A1 (ru) Синергитическая композиция
EA200001176A1 (ru) Гетероциклические ингибиторы p38
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
NO983431D0 (no) Anti-kl°emidler
DE60208068D1 (de) Benzamidinderivate als antagonisten von orexinrezeptoren
DE69414398D1 (de) Heterocyclische neurokinin-antagonisten
PT1440059E (pt) Derivados do 3-azabiciclo(3.1.0)hexano como antagonistas de receptores opióides
IL184121A0 (en) Urotensin-ii agonists polypeptide and its use for manufacture of medicaments
ATE363531T1 (de) Claudin polypeptide
ATE306272T1 (de) Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion
DE60314896D1 (de) 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert
DE60236212D1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
ATE279923T1 (de) Urotensin-ii rezeptorantagonisten
EP1878743A3 (en) Urotensin-II agonists and antagonists
SE0001373D0 (sv) NPY Y1 receptor agonists and antagonists
IS8388A (is) Blandan af serótónín endurupptökuhindra og histamín 3 viðtaka mótlyfi, öflugum verka eða hlutaverka
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
EA200400116A1 (ru) Сочетание действующих веществ для фармакологического лечения никотиновой зависимости
ITFI20030238A1 (it) Peptidi ciclici antagonisti dell'urotensina-ii
EP1463817A4 (en) HISTAMINE RECEPTOR H3 POLYNUCLEOTIDES
ATE320005T1 (de) Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptor